Media stories about Fluidigm (NASDAQ:FLDM) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fluidigm earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 45.1704638212317 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Separately, ValuEngine cut Fluidigm from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 9th.
Shares of Fluidigm (NASDAQ:FLDM) traded up $0.27 during trading on Friday, hitting $6.59. The stock had a trading volume of 191,724 shares, compared to its average volume of 210,497. The company has a debt-to-equity ratio of 5.00, a quick ratio of 2.46 and a current ratio of 3.02. The firm has a market capitalization of $254.69, a price-to-earnings ratio of -2.96 and a beta of 3.37. Fluidigm has a twelve month low of $2.52 and a twelve month high of $8.04.
In other news, insider Levin Capital Strategies, L.P. acquired 6,880 shares of the business’s stock in a transaction dated Friday, November 17th. The stock was acquired at an average price of $5.05 per share, for a total transaction of $34,744.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders bought 503,068 shares of company stock valued at $2,679,781. Insiders own 4.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Fluidigm (FLDM) Given Daily Media Sentiment Score of 0.16” was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.thestockobserver.com/2018/01/13/fluidigm-fldm-given-daily-media-sentiment-score-of-0-16.html.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.